Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rayaldee in symptomatic SARS-CoV-2 infection
NCT04551911Phase 2Completed
- Sponsor
- OPKO Health
- Start
- Nov 2020
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Rayaldee with Placebo (2 arms). Primary endpoints: Concentration of Serum Total 25-hydroxyvitamin D Attained at or Above 50 ng/mL at Day 14 and Resolution of COVID-19 Five Aggregated Symptoms Using the Flu-PRO Plus Questionnaire at Day 42. Started Nov 2020; status: completed.
02
Drugs
calcifediol
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04551911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551911.